Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228992 · ClinicalTrials.gov registry record · Phase 4
Ibuprofen Versus Placebo For Muscle Soreness
A Phase 4 study of Muscle Soreness, sponsored by Jean Brown Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT03228992: Completed Phase 4 study of Muscle Soreness, sponsored by Jean Brown Research.
NCT03228992 is a Phase 4 study of Muscle Soreness that has completed, run by Jean Brown Research. The registered enrollment target is 31 participants, roughly in line with the 30-participant average among 4 other Muscle Soreness trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03228992, a Phase 4 study of Muscle Soreness, has completed, sponsored by Jean Brown Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess the sensitivity of the Delayed Onset Muscle Soreness Model by comparing the safety and efficacy of oral ibuprofen to placebo over 24 hours.
Primary Outcome
Assess whether ibuprofen provides more relief than placebo in the DOMS model.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ibuprofen 400 mg
Study Locations (1)
Utah
- Jean Brown Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-04-10 |
| Est. Completion | 2017-07-31 |
| Phase | Phase 4 |
What the finished NCT03228992 record still lists
NCT03228992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, roughly in line with the 30-participant average among 4 other Muscle Soreness trials with a reported enrollment target.
The record links to 1 condition, with Muscle Soreness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03228992 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT03228992 about?
NCT03228992 is a clinical study titled "Ibuprofen Versus Placebo For Muscle Soreness". The study will assess the sensitivity of the Delayed Onset Muscle Soreness Model by comparing the safety and efficacy of oral ibuprofen to placebo over 24 hours.
What is the current status of trial NCT03228992?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2017-04-10. Estimated completion is 2017-07-31.
What conditions does trial NCT03228992 study?
This clinical trial studies the following conditions: Muscle Soreness.
What interventions are being tested in trial NCT03228992?
The interventions under investigation include: Placebo (OTHER), Ibuprofen 400 mg (DRUG).
Who is sponsoring clinical trial NCT03228992?
This trial is sponsored by Jean Brown Research, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03228992 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Soreness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI